TransCode Therapeutics shares are trading higher after the company announced it's dosed patients in the first cohort of its Phase 1A dose-escalation clinical trial of TTX-MC138.
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics shares rose as the company dosed patients in the first cohort of its Phase 1A dose-escalation trial for TTX-MC138.
October 10, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode Therapeutics' stock price increased following the announcement of dosing patients in the first cohort of its Phase 1A clinical trial for TTX-MC138.
The initiation of patient dosing in a clinical trial is a significant milestone for biotech companies, often leading to positive investor sentiment and stock price increases. This news directly impacts TransCode Therapeutics, as it marks progress in their clinical development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100